- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
3 Million Canadians Embrace GLP-1 Drugs, Reshaping Health and Finances
Survey reveals significant impact of weight loss and diabetes medications on eating habits and spending
Apr. 10, 2026 at 8:26am
Got story updates? Submit your updates here. ›
An X-ray view of the human digestive system reveals the intricate biological mechanisms impacted by GLP-1 medications, highlighting the complex relationship between these drugs and the body.Kansas City TodayA recent survey by Leger Healthcare reveals a growing trend in Canada, with 3 million adults now using GLP-1 drugs, primarily for weight loss and diabetes management. The survey findings suggest these medications are transforming users' relationship with food and finances, with 50% reporting reduced appetite, 40% experiencing fewer cravings, and 30% dining out less frequently. However, the survey also highlights concerns around potential eating disorders and the financial barrier posed by the high cost of these drugs, with 8% of respondents interested but not using them due to affordability issues.
Why it matters
The survey on GLP-1 drug usage in Canada sheds light on the broader implications of these medications, which go beyond just health outcomes. The data suggests these drugs are influencing lifestyle choices, spending habits, and potentially raising concerns about disordered eating. As the use of GLP-1 medications continues to grow, understanding the full impact on individuals and the healthcare system will be crucial.
The details
The Leger Healthcare survey found that among GLP-1 drug users in Canada, 50% reported a reduced appetite, and 40% experienced fewer food cravings. This has led to a shift in eating patterns, with 30% of users dining out or ordering takeout less frequently. While this may indicate healthier choices, the survey also raises questions about potential eating disorders, as weight loss appears to be the primary motivation for most users, with diabetes management as a close second.
- The Leger Healthcare survey was conducted in early 2026.
The players
Leger Healthcare
A Canadian market research firm that conducted the survey on GLP-1 drug usage in Canada.
What’s next
The survey findings highlight the need for further research and discussion around the long-term impacts of GLP-1 drugs, both on individual health and the broader healthcare landscape. Policymakers and healthcare providers will likely need to address issues of affordability and potential risks associated with these medications.
The takeaway
The survey on GLP-1 drug usage in Canada reveals a complex picture, with the medications potentially offering benefits in terms of weight management and diabetes control, but also raising concerns about disordered eating and financial accessibility. As the use of these drugs continues to grow, understanding the full implications will be crucial for supporting the health and well-being of Canadians.
